San Diego??'s Amplyx Bags $67 Million to Advance APX001 into Clinical Development
August 2, 2017 - Amplyx Pharmaceuticals, a company developing novel antifungal agents for life-threatening fungal infections, today announced that it has raised $67 million through a Series C financing led by Sofinnova Venture Partners and including other new investors Lundbeckfonden Ventures, Arix Bioscience and Pappas Capital. Existing investors New Enterprise Associates, RiverVest Venture Partners, 3 5 RiverVest II and BioMed Ventures also participated in the financing.
Start the conversation, or Read more at BioSpace.
Copyright © 2018 Topix LLC